Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885774 | 0.86 | CXCR4 (0.47) | PDE10AACHEGPR119USP30DDB1 | |
| SCHEMBL4895659 | 0.84 | ADRB1 (0.38) | PDE10A | |
| Trifluoroacetic Acid SCHEMBL4889301 | 0.82 | CXCR4 (0.44) | PDE10AACHEDDB1CRBNGBA1 | |
| SCHEMBL4178891 | 0.75 | CKS1B (0.43) | ACHEGPR119POLBMAPTGBA1 | |
| SCHEMBL4885422 | 0.74 | CXCR4 (0.49) | PDE10AACHEGPR119DDB1CRBN | |
| SCHEMBL4882709 | 0.73 | CXCR4 (0.51) | — | |
| SCHEMBL4177280 | 0.72 | CXCR4 (0.47) | PDE10AACHEGPR119POLBGBA1 | |
| SCHEMBL4885398 | 0.72 | CXCR4 (0.47) | FNTAFNTB | |
| SCHEMBL4163673 | 0.72 | ACHE (0.42) | ACHEGPR119MAPTGBA1BACE1 | |
| SCHEMBL4887206 | 0.72 | BACE1 (0.51) | ACHEMAPTGBA1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214562-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | PDE10A 2500/4885ACHE 4784/4885GPR119 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.